M&A Deal Summary

ViroPharma Acquires Lev Pharmaceuticals

On October 21, 2008, ViroPharma acquired life science company Lev Pharmaceuticals for 586M USD

Acquisition Highlights
  • This is ViroPharma’s 1st transaction in the Life Science sector.
  • This is ViroPharma’s largest (disclosed) transaction.
  • This is ViroPharma’s 1st transaction in the United States.
  • This is ViroPharma’s 1st transaction in New York.

M&A Deal Summary
Date 2008-10-21
Target Lev Pharmaceuticals
Sector Life Science
Buyer(s) ViroPharma
Deal Type Add-on Acquisition
Deal Value 586M USD
Advisor(s) Willkie Farr & Gallagher
Becker (Legal)

Target

Lev Pharmaceuticals

New York, New York, United States
Lev Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ViroPharma

Exton, Pennsylvania, United States
Category Company
Founded 1994
Sector Life Science
DESCRIPTION

ViroPharma, Inc. is a pharmaceutical company committed to the commercialization, development, and discovery of new antiviral medicines.

DEAL STATS #
Overall 1 of 3
Sector (Life Science) 1 of 3
Type (Add-on Acquisition) 1 of 3
State (New York) 1 of 1
Country (United States) 1 of 1
Year (2008) 1 of 1
Size (of disclosed) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2010-05-28 Auralis

Halton, United Kingdom

Auralis developed generic pharmaceutical products for niche markets, which were subject to licence or regulatory approval providing barriers to entry to protect margin and revenue.

Buy -
Mergr

Product

Company

Legal